Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies

Breast

Volumn 12, Issue SUPPL. 2, 2003, Pages

  Cameron, David ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID; IMIDAZOLE DERIVATIVE;

ANEMIA; ANOREXIA; BLADDER CANCER; BONE DENSITY; BONE METASTASIS; BONE MINERAL; BONE PAIN; BREAST CANCER; BREAST METASTASIS; CALCIUM BLOOD LEVEL; CANCER INHIBITION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; HUMAN; HYPERCALCEMIA; IC 50; KIDNEY CANCER; LUNG CANCER; METASTASIS; MORBIDITY; MULTIPLE MYELOMA; MYALGIA; NAUSEA; OSTEOLYSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZATION; REVIEW; SIDE EFFECT; SPINAL CORD COMPRESSION; VOMITING; BONE TUMOR; BREAST TUMOR; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROSTATE TUMOR; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM;

BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; OSTEOLYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 11144336663     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(03)80160-1     Document Type: Article

References (45)

1. Rubens R D, Coleman R E. Bone metastases. In: Abeloff M D, Armitage J O, Litchter A S, et al. (eds) Clinical Oncology. New York: Churchill Livingstone, 1995; 643-648.
2. Rodan G A, Fleisch H A. Bisphosphonates: mechanisms of action. J Clin Invest 1996; 97: 2692-2696.
3. Elomaa I, Blomqvist C. Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy. Acta Oncol 1995; 34: 629-636.
4. Elomaa I, Blomqvist C, Grohn P, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983; 1: 146-149.
5. Paterson A H, Powles T J, Kanis J A, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
6. Clemens M R, Fessele K, Heim M E. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann Hematol 1993; 66: 141-146.
7. McCloskey E V, Dunn J A, Kanis J A, MacLennan I C M, Drayson M T. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001; 113: 1035-1043.
8. Berenson J R, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16: 593-602.
9. Hortobagyi G N, Theriault R L, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996; 335: 1785-1791.
10. Hortobagyi G N, Theriault R L, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038-2044.
11. Theriault R L, Lipton A, Hortobagyi G N, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846-854.
12. Green J R, M ller K, Jaeggi K A. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-751.
13. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19: 558-567.
14. Rosen L S, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
15. Rosen L, Gordon D, Tchekmedyian S, et al. Zoledronic acid (Zol) significantly reduces skeletal-related events (SREs) in patients with bone metastases from solid tumors. Proc Am Soc Clin Oncol 2002; 21: 295a [abstract 1179].
16. Saad F, Gleason D M, Murray R, et al. Zoledronic acid reduces skeletal complications in patients with hormone-refractory prostate carcinoma metastatic to bone: a randomized, placebo-controlled trial. J Natl Cancer Inst 2002; 94: 1458-1468.
17. Pataki A, M ller K, Green J R, Ma Y F, Li Q N, Jee W S S. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 1997; 249: 458-468.
18. Binkley N, Kimmel D, Bruner J, et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 1998; 13: 1775-1782.
19. Bare S, Kimmel D, Binkley N, Schaffer V, Green J. Zoledronate (CGP 42,446) suppresses turnover without affecting mineralization in cancellous bone of the ovariectomized non-human primate. J Bone Miner Res 1997; 12(suppl 1): S473 [abstract S482].
20. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12: 220-229.
21. Derenne S, Amiot M, Barill S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999; 14: 2048-2056.
22. Hiraga T, Williams P J, Mundy G R, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001; 61: 4418-4424.
23. Lee M V, Fong E M, Singer F R, Guenette R S. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602-2608.
24. Mackie P S, Fisher J L, Zhou H, Choong P F. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001; 84: 951-958.
25. Senaratne S G, Pirianov G, Mansi J L, Arnett T R, Colston K W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459-1468.
26. Corey E, Quinn J E, Brown L G, Roudier M P M, Higano C, Vessella R L. Examination of effects of zoledronic acid on prostate cancer. J Bone Miner Res 2001; 16(suppl 1): S192 [abstract F070].
27. Croucher P I, Hijzen A, Shipman C M, et al. Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma. Blood 2001; 98: 160a [abstract 674].
28. Green J, Gschaidmeier H, Yoneda T, Mundy G. Zoledronic acid potently inhibits tumour-induced osteolysis in two models of breast cancer metastasis to bone. Ann Oncol 2000; 11(suppl 4): 14 [abstract 50P].
29. Nobuyuki H, Hiraga T, Williams P J, et al. The bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumor. J Bone Miner Res 2001; 16(suppl 1): S191 [abstract F062].
30. Peyruchaud O, Winding B, Pecheur I, Serre C-M, Delmas P, Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001; 16: 2027-2034.
31. Yaccoby S, Pearse R N, Johnson C L, Barlogie B, Choi Y, Epstein J. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002; 116: 278-290.
32. Berenson J R, Vescio R, Henick K, et al. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001; 91: 144-154.
33. Berenson J R, Vescio R A, Rosen L S, et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001; 7: 478-485.
34. Berenson J R, Rosen L S, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: a double-blind, randomized dose-response study. Cancer 2001; 91: 1191-1200 [published erratum appears in Cancer 2001; 91: 1956].
35. Cook R J, Major P. Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 2001; 93: 534-538.
36. Windeler J, Lange S. Events per person year - a dubious concept. BMJ 1995; 310: 454-456.
37. Andersen P K, Gill R D. Cox's regression model for counting processes: a large sample study. The Annals of Statistics 1982; 10: 1100-1120.
38. Rosen L, Gordon D H, Gleason D, Saad F. Broad clinical utility of zoledronic acid in the treatment of lytic to blastic bone metastases. Presented at What's New In Bisphosphonates? Sixth Workshop on Bisphosphonates - From the Laboratory to the Patient, Davos, Switzerland, 20-22 March 2002 [poster 63].
39. Rosen L, Gordon D H, Dugan W Jr, et al. Zoledronic acid (4 mg) is more effective than pamidronate (90 mg) for treating bone metastases in breast cancer patients with at least one osteolytic lesion. Presented at European Society of Medical Oncology Congress, Nice, France, 18-22 October 2002 [abstract 629].
40. Small E J, Smith M R, Seaman J J, Ortu Kowalski M. A multicenter, randomized, placebo-controlled study of pamidronate disodium for the palliation of bone pain in patients with advanced prostate cancer. J Clin Oncol (in press).
41. Ernst D S, Tannock I F, Venner P M, et al. Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. Proc Am Soc Clin Oncol 2002; 21: 177a [abstract 705].
42. Elomaa I, Kylmala T, Tammela T, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostate cancer. Int Urol Nephrol 1992; 24: 159-166.
43. Rosen L, Gordon D, Tchekmedyian S, et al. Zoledronic acid significantly reduced the occurrence of skeletal related events (SREs) in patients with osteolytic bone metastases from non-small cell lung cancer (NSCLC) and other solid tumors (OST). Presented at 3rd International Congress on Prevention and Early Detection of Lung Cancer, Reykjavik, Iceland, 9-12 August 2001 [abstract].
44. Smith M R, Shasha D, Mansour R, et al. Zometa increases bone mineral density in men undergoing androgen deprivation therapy for prostate cancer. Presented at 3rd North American Symposium: Skeletal Complications of Malignancy, Bethesda, Maryland, 25-27 April 2002 [abstract].
45. Reid I R, Brown J P, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-661.